In our multicenter European study involving 1020 patients with Gleason grade group ≥2 prostate cancer on magnetic resonance imaging–targeted biopsy, the rate of downgrading at radical prostatectomy specimen was 17.5%, but the overall risk of targeted biopsy–induced overtreatment was only ∼2.7%. Our findings indicate that targeted biopsy results are accurate and should be used for decision-making without fearing overtreatment caused by imaging guidance.

中文翻译：

---

前列腺癌磁共振成像可见病变的靶向活检过度分级是否会导致过度治疗？

在我们的欧洲多中心研究中，对 1020 名 Gleason 分级≥2 级前列腺癌患者进行磁共振成像靶向活检，根治性前列腺切除标本的降级率为 17.5%，但靶向活检引起过度治疗的总体风险仅为 ∼2.7 %。我们的研究结果表明，靶向活检结果是准确的，应该用于决策，而不必担心影像引导导致的过度治疗。